Advertisement

Reply

Published:December 05, 2014DOI:https://doi.org/10.1016/j.amjcard.2014.11.017
      We would like to thank Buisson et al
      • Buisson M.
      • Cornu C.
      • Nony P.
      Erroneous event count in a meta-analysis (DPP 4 inhibitors in type 2 diabetes mellitus).
      for discovering the error in our previous meta-analysis and commend them for their diligence. We have reviewed the raw numbers of major adverse cardiovascular events (MACE) from our previous meta-analysis
      • Patil H.R.
      • Al Badarin F.J.
      • Al Shami H.A.
      • Bhatti S.K.
      • Lavie C.J.
      • Bell D.S.
      • O'Keefe J.H.
      Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
      and confirmed that the MACE we recorded from the report by Chan et al
      • Chan J.C.
      • Scott R.
      • Arjona Ferreira J.C.
      • Sheng D.
      • Gonzalez E.
      • Davies M.J.
      • Stein P.P.
      • Kaufman K.D.
      • Amatruda J.M.
      • Williams-Herman D.
      Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
      were erroneous. In retrospect, the 2 abstracters recording this information both inadvertently used the events listed in Table 5 of the report by Chan et al, which depicted projected events per 100 patient-years of therapy (10 and 12 for sitagliptin and control groups, respectively), rather than actual events as listed in Table 4 of the report by Chan et al (11 and 1 for sitagliptin and control groups, respectively). After correcting this numerical error, the point estimate for the pooled analysis showed that DPP4 inhibitors no longer had a statistically significant effect on MACE, as pointed out by Buisson et al.
      • Buisson M.
      • Cornu C.
      • Nony P.
      Erroneous event count in a meta-analysis (DPP 4 inhibitors in type 2 diabetes mellitus).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Buisson M.
        • Cornu C.
        • Nony P.
        Erroneous event count in a meta-analysis (DPP 4 inhibitors in type 2 diabetes mellitus).
        Am J Cardiol. 2015; 115: 852
        • Patil H.R.
        • Al Badarin F.J.
        • Al Shami H.A.
        • Bhatti S.K.
        • Lavie C.J.
        • Bell D.S.
        • O'Keefe J.H.
        Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.
        Am J Cardiol. 2012; 110: 826-833
        • Chan J.C.
        • Scott R.
        • Arjona Ferreira J.C.
        • Sheng D.
        • Gonzalez E.
        • Davies M.J.
        • Stein P.P.
        • Kaufman K.D.
        • Amatruda J.M.
        • Williams-Herman D.
        Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
        Diabetes Obes Metab. 2008; 10: 545-555
        • Scirica B.M.
        • Bhatt D.L.
        • Braunwald E.
        • Steg P.G.
        • Davidson J.
        • Hirshberg B.
        • Ohman P.
        • Frederich R.
        • Wiviott S.D.
        • Hoffman E.B.
        • Cavender M.A.
        • Udell J.A.
        • Desai N.R.
        • Mosenzon O.
        • McGuire D.K.
        • Ray K.K.
        • Leiter L.A.
        • Raz I.
        Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
        N Engl J Med. 2013; 369: 1317-1326
        • White W.B.
        • Cannon C.P.
        • Heller S.R.
        • Nissen S.E.
        • Bergenstal R.M.
        • Bakris G.L.
        • Perez A.T.
        • Fleck P.R.
        • Mehta C.R.
        • Kupfer S.
        • Wilson C.
        • Cushman W.C.
        • Zannad F.
        Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
        N Engl J Med. 2013; 369: 1327-1335

      Linked Article

      • Erroneous Event Count in a Meta-Analysis (Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus)
        American Journal of CardiologyVol. 115Issue 6
        • Preview
          We identified an erroneous event number in the report by Patil et al1 entitled “Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus,” published in the (2012) 110th issue of The American Journal of Cardiology. Figures presented in the meta-analysis are not consistent with the data from the report by Chan et al2 entitled “Safety and Efficacy of Sitagliptin in Patients With Type 2 Diabetes and Chronic Renal Insufficiency” published in the tenth issue of Diabetes, Obesity and Metabolism (2008).
        • Full-Text
        • PDF